References

1. Polaneczky M, Slap G, Forke C, Rappaport A, Sondheimer S (1994) The use of levonorgestrel implants (Norplant) for contraception in adolescent mothers. N Engl J Med 331: 1201-1206 [CrossRef] [Google Scholar] [PubMed]
2. Lara-Torre E (2004) "Quick Start", an innovative approach to the combination oral contraceptive pill in adolescents. Is it time to make the switch? J Pediatr Adolesc Gynecol 17: 65-67 [CrossRef] [Google Scholar] [PubMed]
3. Coffee A, Sulak PJ, Kuehl TJ (2007) Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen. Contraception 75: 444-449 [CrossRef] [Google Scholar] [PubMed]
4. Edelman , Gallo MF, Nichols MD, Jensen JT, Schulz KF, et al. (2006) Continuous versus cyclic use of combined oral contraceptives for contraception: systematic Cochrane review of randomized controlled trials. Hum Reprod 21: 573-578 [CrossRef] [Google Scholar] [PubMed]
5. [No authors listed] (2005) 'Black box' warning added to contraceptive injection. FDA Consum 39: 3 [PubMed]
6. Cromer BA, Scholes D, Berenson A, Cundy T, Clark MK, et al. (2006) Depot medroxyprogesterone acetate and bone mineral density in adolescents- -the Black Box Warning: a Position Paper of the Society for Adolescent Medicine. J Adolesc Health 39: 296-301 [CrossRef] [Google Scholar] [PubMed]
7. Vandenbroucke JP, Rosing J, Bloemenkamp KW, Middeldorp S, Helmerhorst FM, et al. (2001) Oral contraceptives and the risk of venous thrombosis. N Engl J Med 344: 1527-1535 [CrossRef] [Google Scholar] [PubMed]
8. Douketis JD, Ginsberg JS, Holbrook A, Crowther M, Duku EK, et al. (1997) A reevaluation of the risk for venous thromboembolism with the use of oral contraceptives and hormone replacement therapy. Arch Intern Med 157: 1522-1530 [CrossRef] [Google Scholar] [PubMed]
9. Bloemenkamp KW, Rosendaal FR, Büller HR, Helmerhorst FM, Colly LP, et al. (1999) Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med 159: 65-70 [CrossRef] [Google Scholar] [PubMed]
10. PhVWP (2012) Monthly report on safety concerns, guidelines and general matters. Europ Medicin Agency [View]
11. Rosing J, Tans G, Nicolaes GA, Thomassen MC, van Oerle R, et al. (1997) Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 97:233-238 [CrossRef] [Google Scholar] [PubMed]
12. Rosing J, Middeldorp S, Curvers J, Christella M, Thomassen LG, et al. (1999) Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 354: 2036-2040 [CrossRef] [Google Scholar] [PubMed]
13. Middeldorp S, Meijers JC, van den Ende AE, van Enk A, Bouma BN, et al. (2000) Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost 84: 4-8 [CrossRef] [Google Scholar] [PubMed]
14. Kemmeren JM, Algra A, Meijers JC, Bouma BN, Grobbee DE (2002) Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation. Thromb Haemost 87: 199-205 [CrossRef] [Google Scholar] [PubMed]
15. Kemmeren JM, Algra A, Meijers JC, Tans G, Bouma BN, et al. (2004) Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial. Blood 103: 927-933 [CrossRef] [PubMed]
16. Sidney S, Petitti DB, Soff GA, Cundiff DL, Tolan KK, et al. (2004) Venous thromboembolic disease in users of low-estrogen combined estrogenprogestin oral contraceptives. Contraception 70: 3-10 [CrossRef] [Google Scholar] [PubMed]
17. Pomp ER, le Cessie S, Rosendaal FR, Doggen CJ (2007) Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol 139: 289-296 [CrossRef] [Google Scholar] [PubMed]
18. Abdollahi M, Cushman M, Rosendaal FR (2003) Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost 89: 493-498 [CrossRef] [Google Scholar] [PubMed]
19. Nightingale AL, Lawrenson RA, Simpson EL, Williams TJ, MacRae KD, et al. (2000) The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users ofcombined oral contraceptives. Eur J Contracept Reprod Health Care 5: 265-274 [CrossRef] [Google Scholar] [PubMed]
20. Louv WC, Austin H, Perlman J, Alexander WJ (1989) Oral contraceptive use and the risk of chlamydial and gonococcal infections. Am J Obstet Gynecol 160: 396-402 [CrossRef] [Google Scholar] [PubMed]
21. Rubin GL, Ory HW, Layde PM (1982) Oral contraceptives and pelvic inflammatory disease. Am J Obstet Gynecol 144: 630-635 [CrossRef] [Google Scholar] [PubMed]
22. Ness RB, Keder LM, Soper DE, Amortegui AJ, Gluck J, et al. (1997) Oral contraception and the recognition of endometritis. Am J Obstet Gynecol 176: 580-585 [CrossRef] [Google Scholar] [PubMed]
23. Wolner-Hanssen P, Svensson L, Mardh PA, Westrom L (1985) Laparoscopic findings and contraceptive use in women with signs and symptoms suggestive of acute salpingitis. Obstet Gynecol 66: 233-238 [CrossRef] [Google Scholar] [PubMed]
24. Ness RB, Soper DE, Holley RL, Peipert J, Randall H, et al. (2001) Hormonal and barrier contraception and risk of upper genital tract disease in the PID Evaluation and Clinical Health (PEACH) study. Am J Obstet Gynecol 185: 121-127 [CrossRef] [Google Scholar] [PubMed]
25. Stanwood NL, Garrett JM, Konrad TR (2002) Obstetrician-gynecologists and the intrauterine device: a survey of attitudes and practice. Obstet Gynecol 99: 275-280 [CrossRef] [Google Scholar] [PubMed]
26. Committee on Adolescent Health Care Long-Acting Reversible Contraception Working Group TACoO (2012) Gynecologists. Committee opinion no. 539: adolescents and long-acting reversible contraception: implants and intrauterine devices. Obstet Gynecol 120: 983-988
27. ACOG Committee Opinion no. 450: Increasing use of contraceptive implants and intrauterine devices to reduce unintended pregnancy. Obstet Gynecol 114:1434-1438 [CrossRef] [PubMed]
28. Teal SB, Romer SE, Goldthwaite LM, Peters MG, Kaplan DW, et al. (2015) Insertion characteristics of intrauterine devices in adolescents and young women: success, ancillary measures, and complications. Am J Obstet Gynecol 213: 515 [CrossRef] [Google Scholar] [PubMed]
29. Medical Eligibility Criteria for Contraceptive Use (2010) A WHO Family Planning Cornerstone. 4th ed Geneva
30. Stanford JB, Mikolajczyk RT (2002) Mechanisms of action of intrauterine devices: update and estimation of postfertilization effects. Am J Obstet Gynecol 187: 1699-1708 [CrossRef] [Google Scholar] [PubMed]
31. Ott MA, Sucato GS (2014) Committee on A. Contracep for adol Pediatric 134: e1257-1281
32. Steiner MJ, Kwok C, Stanback J, Byamugisha JK, Chipato T, et al. (2008) Injectable contraception: what should the longest interval be for reinjections? Contracept 77: 410-414 [CrossRef] [Google Scholar] [PubMed]
33. Mulders TM, Dieben TO (2001) Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. Fertil Steril. 75: 865-870 [CrossRef] [Google Scholar] [PubMed]
34. Barreiros FA, Guazzelli CA, Barbosa R, de Assis F, de Araujo FF (2010) Extended regimens of the contraceptive vaginal ring: evaluation of clinical aspects. Contracept 81: 223-225 [CrossRef] [Google Scholar] [PubMed]
35. Miller L, Verhoeven CH, Hout J (2005)Extended regimens of the contraceptive vaginal ring: a randomized trial. Obstet Gynecol 106 :473- 482 [CrossRef] [Google Scholar] [PubMed]
36. Barreiros FA, Guazzelli CA, de Araujo FF, Barbosa R (2007) Bleeding patterns of women using extended regimens of the contraceptive vaginal ring. Contraception 75: 204-208 [CrossRef] [Google Scholar] [PubMed]
37. Guazzelli CA, Barreiros FA, Barbosa R, de Araujo FF, Moron AF (2009) Extended regimens of the vaginal contraceptive ring: cycle control. Contraception 80: 430-435 [CrossRef] [Google Scholar] [PubMed]
38. Barreiros FA, Guazzelli CA, Barbosa R, Torloni MR, Barbieri M, et al. (2011) Extended regimens of the combined contraceptive vaginal ring containing etonogestrel and ethinyl estradiol: effects on lipid metabolism. Contraception. 84: 155-159 [CrossRef] [Google Scholar] [PubMed]
39. Zacur HA, Hedon B, Mansour D, Shangold GA, Fisher AC, et al. (2002) Integrated summary of Ortho Evra/Evra contraceptive patch adhesion in varied climates and conditions. Fertil Steril 77: S32-35 [CrossRef] [Google Scholar] [PubMed]
40. Kapp N, Abitbol JL, Mathé H, Scherrer B, Guillard H, et al. (2015) Effect of body weight and BMI on the efficacy of levonorgestrel emergency contraception. Contraception 91: 97-104 [CrossRef] [Google Scholar] [PubMed]
41. Levonorgestrel and ulipristal remain suitable emergency contraceptives for all women, regardless of bodyweight
42. Salcedo J, Rodriguez MI, Curtis KM, Kapp N (2013) When can a woman resume or initiate contraception after taking emergency contraceptive pills? A systematic review. Contracep 87: 602-604 [CrossRef] [Google Scholar] [PubMed]
43. Practice Bulletin No. 152 (2015) Emergency Contraception. Obstet Gynecol 126: e1-e11 [CrossRef] [PubMed]
44. Ulipristal acetate. US FDA approved product information. National Library of Medicine
45. Clinical Effectiveness Unit (2011) Combined hormonal contraception. London (UK): Faculty of Sexual and Reproductive Healthcare